
CLAIMS:

1. A compound of formula (I),



(I)

wherein

A is selected from the group consisting of:

(a) C_5-C_7-cycloalkylene which is unsubstituted or substituted with one or more, preferably 1, 2 or 3, substituents independently selected from fluoro and C_1-C_4-alkyl;

(b) a 5-7 membered unsaturated heterocyclyl containing one carbon-carbon double bond and one oxygen atom as ring member, wherein said heterocyclyl is unsubstituted or substituted with one or more , preferably 1, 2 or 3, substituents, independently selected from fluoro and C_1-C_4-alkyl, preferably 1, 2 or 3, C_1-C_4-alkyl;

(c) C_6-C_{10} aryl which is unsubstituted or substituted with 1, 2 or 3 R^{A2};

(d) a 5-6 membered heteroaryl ring containing 1, 2 or 3 heteroatoms independently selected from N, O and S as ring members, wherein said heteroaryl ring is unsubstituted or substituted on one or more (e.g., 1, 2 or 3) carbon atoms with R^{A3}, and wherein a nitrogen atom, when present in the heteroaryl ring, is unsubstituted or substituted with a substituent selected from the group consisting of: C_1-C_4-alkyl, $–(CH_2)_{1-2}$-C_{3-4}-cycloalkyl, C_3-C_6-cycloalkyl, hydroxy-C_1-C_4-alkyl, fluoro-C_1-C_4-alkyl, C_1-C_4-alkoxy-C_1-C_4-alkyl, $N(R^9)(R^{10})$-C_1-C_4-alkyl, $-SO_2$-C_1-C_4-alkyl, $-SO_2$-C_{3-4}-cycloalkyl, $–(CH_2)_p$-Het^{py}, and $-(CH_2)_p–N(R^9)(R^{10})$;

(e) an 8-10 membered heteroaryl ring containing 1 to 3 heteroatoms independently selected from nitrogen, oxygen and sulfur, or an 8-10 membered partially saturated hetero-bicyclic ring containing 1 to 3 heteroatoms or heteroatom groups independently selected from 0-3 nitrogen atoms, 0-2 oxygen atoms, 0-1 sulfur atom and 0-1 $S(=O)_2$ group in the hetero-bicyclic ring, wherein said heteroaryl ring or hetero-bicyclic ring is unsubstituted or substituted on a carbon atom with 1, 2, 3, 4 or 5 R^{A4}, and wherein the hetero-bicyclic ring is further optionally substituted

on a carbon atom by oxo and wherein a nitrogen atom, when present, is unsubstituted or substituted with a substituent which is –(CO)-C_1-C_4-alkyl or C_1-C_4-alkyl, and wherein said C_1-C_4-alkyl is optionally substituted with 1 or 2 substituents independently selected from cyano, hydroxy, oxo, fluoro, C_1-C_4-alkoxy, C_1-C_4-alkoxy-C_1-C_4-alkyl-oxy, Het^b and NR^9R^{10}; and

wherein Het^b is a 4- or 5- or 6- membered heterocyclic ring comprising 1 or 2 heteroatoms or groups independently selected from N, O, S, SO and SO_2, wherein said heterocyclic ring Het^b is unsubstituted or substituted on a carbon atom with one or two substituents independently selected from C_1-C_4-alkyl, hydroxy, cyano, fluoro, C_1-C_4-alkoxy-hydroxy-C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl, C_1-C_4-alkoxy, fluoro-C_1-C_4-alkoxy and fluoro-C_1-C_4-alkyl, and wherein said heterocyclic ring Het^b is further optionally substituted on a carbon atom by oxo, and wherein the nitrogen atom when present in Het^b is optionally further substituted with C_1-C_4-alkyl which is optionally substituted with 1 to 3 substituents independently selected from fluoro, hydroxy and C_1-C_4-alkoxy;

wherein A is attached to the rest of the compound of Formula (I) by a carbon atom on A which is sp^2 hybridized;

wherein


B is selected from the group consisting of B^1 and B^2,

wherein B^1 is $C_{6\text{-}10}$ aryl which is unsubstituted or substituted with 1, 2, 3 or 4 R^{Ba};

B^2 is a 6-13 membered heteroaryl which comprises 1, 2 or 3 nitrogen atoms, wherein B^2 is unsubstituted or substituted with 1, 2, 3 or 4 R^{Bb};

C is selected from the group consisting of hydrogen, C_1-C_3 alkyl, C_3-C_5 cycloalkyl, fluoro-C_1-C_3 alkyl, cyano, –CH_2–CN, –CH(CN)-CH_3, –CH_2–OH, –CH(OH)-CH_3 and halo;

L is selected from the group consisting of:




wherein n is 1, 2 or 3,

R_L is selected from hydrogen, methyl, ethyl, $–CH_2–CN$ and $–CH_2–OH$, where

G* represents the point of attachment to G;

G is selected from the group consisting of



;

wherein

R^2 is selected from hydrogen, C_1-C_3 alkyl, -C(O)-C_1-C_3-alkyl, and fluoro;

R^3 is hydrogen;

R^4 is selected from hydrogen, methyl, $–CH_2F$, $–CH_2$-OCH_3 and $–CH_2$-$N(CH_3)_2$;

R^5 is selected from hydrogen and methyl;

R^6 is hydrogen;

R^7 is selected from hydrogen and methyl;

wherein R^{A2} is independently selected from the group consisting of: NR^9R^{10}, cyano, -$(CH_2)_p$-CN, halo, OH, hydroxy-C_1-C_4-alkyl, –(COOH), –$(CH_2)_p$-COOH, C_1-C_4-alkyl, fluoro-C_1-C_4-alkyl, C_1-C_4-

alkoxy, C_1-C_4-alkoxy-C_1-C_4-alkyl, N(R^9)(R^{10})-C_1-C_4-alkyl, N(R^9)(R^{10})-C_1-C_4-alkyl-oxy, N(R^9)(R^{10})-C_1-C_4-alkoxy, C_1-C_4-alkyl-carbonyl-oxy-C_1-C_4-alkyl-oxy, hydroxy-C_1-C_4-alkyl-oxy, C_1-C_4-alkoxy-C_1-C_4-alkyl-oxy, C_1-C_4-alkoxy-C_1-C_4-alkyl-oxy-C_1-C_4-alkyl, -SO_2-C_1-C_4-alkyl, -SO_2-C_{3-4}-cycloalkyl, –$(CH_2)_{1-2}$-C_{3-4}-cycloalkyl, Het^{py}, -$(CH_2)_p$-Het^{py}, –C(=O)-NR^9R^{10}, -$(CH_2)_p$-C(=O)NR^9R^{10};

wherein R^{A3} is independently selected from the group consisting of oxo, NR^9R^{10}, cyano, -$(CH_2)_p$-CN, halo, OH, hydroxy-C_1-C_4-alkyl, –(COOH), –$(CH_2)_p$-COOH, C_1-C_4-alkyl, fluoro-C_1-C_4-alkyl, C_1-C_4-alkoxy, C_1-C_4-alkoxy-C_1-C_4-alkyl, N(R^9)(R^{10})-C_1-C_4-alkyl, N(R^9)(R^{10})-C_1-C_4-alkyl-oxy, N(R^9)(R^{10})-C_1-C_4-alkoxy, C_1-C_4-alkyl-carbonyl-oxy-C_1-C_4-alkyl-oxy, hydroxy-C_1-C_4-alkyl-oxy, C_1-C_4-alkoxy-C_1-C_4-alkyl-oxy, C_1-C_4-alkoxy-C_1-C_4-alkyl-oxy-C_1-C_4-alkyl, -SO_2-C_1-C_4-alkyl, -SO_2-C_{3-4}-cycloalkyl, –$(CH_2)_{1-2}$-C_{3-4}-cycloalkyl, Het^{py}, -$(CH_2)_p$-Het^{py}, –C(=O)-NR^9R^{10}, -$(CH_2)_p$-C(=O)NR^9R^{10}, $(CH_2)_p$–NR^9R^{10};

wherein R^{A4} is independently selected from the group consisting of cyano, CO_2H, halo, C_1-C_4-alkyl, fluoro-C_1-C_4-alkyl, hydroxy, hydroxy-C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl-oxy, C_1-C_4-alkoxy, C_1-C_4-alkoxy-C_1-C_4-alkyl, C_1-C_4-alkoxy-C_1-C_4-alkyl-oxy, NR^9R^{10}, (N(R^9)(R^{10})-C_1-C_4-alkyl, (N(R^9)(R^{10})-C_1-C_4-alkyl-oxy, –(CO)-C_1-C_4-alkyl, and R^9R^{10}N-C_1-C_4-alkyl-oxy–(CO)-C_1-C_4-alkyl;

wherein

p is 1 or 2 or 3;

R^9 is selected from hydrogen and C_1-C_4-alkyl;

R^{10} is selected from the group consisting of hydrogen, C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl, C_1-C_4-alkoxy-C_1-C_4-alkyl and di-C_1-C_4-alkyl-amino-C_1-C_4-alkyl;

Het^{py} is a 4-, 5-, 6- or 7-membered saturated heterocyclic ring comprising one or two heteroatoms independently selected from O, N and S, or comprising an S-oxide (SO) or S-dioxide (SO_2) group, and wherein said heterocyclic ring is optionally substituted with oxo on one carbon atom, and wherein said heterocyclic ring is optionally further substituted on one or more carbon atoms with 1, 2 or 3 substituents independently selected from C_1-C_4-alkoxy, halo, C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl, and fluoro-C_1-C_4-alkyl, and wherein the nitrogen atom, if present in said heterocycle, is optionally further substituted with R^{10};


or Het^{py} is a 5- or 6- membered heteroaryl ring, comprising 1, 2 or 3 nitrogen atoms and wherein said heteroaryl ring is optionally substituted with one or more (e.g., 1, 2 or 3) substituents independently selected from NR^9R^{10}, –C(=O)-NR^9R^{10}, halo, C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl, fluoro-C_1-C_4-alkyl, cyano, OH, and C_1-C_4-alkoxy;

each R^{Ba} is independently selected from the group consisting of hydroxy, NH_2, C_1-C_4-alkyl and halo;

each R^{Bb} is independently selected from the group consisting of C_1-C_4-alkyl, cyclopropyl, fluoro-C_1-C_3-alkyl, cyano, halo, NH_2 and C_1-C_3-alkoxy,

or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.


2. A compound according to claim 1 wherein G is



,

or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

3. A compound according to claim 1 or 2, wherein L is




,

and R_L is selected from hydrogen, methyl, ethyl, $–CH_2–CN$ and $–CH_2–OH$,

or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

4. A compound according to any one of the preceding claims, wherein C is selected from C_1-C_3 alkyl, fluoro-C_1-C_3 alkyl, $CH_2–CN$, or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

5. A compound according to any one of the preceding claims, wherein B is



,

where X is N or C-R^{B5};

where R^{B1} is independently selected from hydrogen and C_1-C_4-alkyl;

R^{B2} is independently selected from hydrogen, halo, C_1-C_4-alkyl, cyclopropyl and NH_2;

R^{B3} is independently selected from hydrogen, halo, cyclopropyl and C_1-C_4-alkyl;

R^{B4} is independently selected from hydrogen, halo and C_1-C_4-alkyl, or R^{B3} and R^{B4} together with the atoms to which they are attached, form a 4-6 membered ring fused to the aromatic ring containing X;

R^{B5} is independently selected from hydrogen, halo and C_1-C_4-alkyl,

or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

6. A compound according to claim 5, wherein R^{B2} is independently selected from the group consisting of hydrogen, NH_2, and CH_3, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.


7. A compound according to claim 5 or 6, wherein R^{B4} is independently selected from hydrogen, halo and C_1-C_4-alkyl, or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

8. A compound according to any one of claims 5 to 7, wherein R^{B1} is independently selected from hydrogen and methyl, or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

9. A compound according to any one of claims 5 to 8, wherein X is CH or N, or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof,

or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

10. A compound of formula (Ia)














(Ia)

,

wherein A, B and C are as defined in any one of the preceding claims, or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

11. A compound of formula (I) or of formula (Ia), according to any one of claims 1 to 10, wherein A is selected from the group consisting of:


,

,

,

,

,

,

,

,

,

and

,

wherein z is 0, 1 or 2;

R^v is independently selected from halogen, C_1-C_4-alkyl and fluoro-C_1-C_4-alkyl;

R is hydrogen or C_1-C_4-alkyl, or halo or fluoro-C_1-C_4-alkyl;

R^O is selected from the group consisting of hydrogen, NR^9R^{10}, $N(R^9)(R^{10})$-C_1-C_4-alkyl-oxy, C_1-C_4-alkoxy-C_1-C_4-alkyl-oxy, hydroxy-C_1-C_4-alkyl-oxy and C_1-C_4-alkyl;

R^{ae} is selected from the group consisting of hydrogen and C_1-C_4-alkyl, wherein said alkyl is optionally substituted with 1 or 2 substituents selected from cyano, hydroxy, fluoro, C_1-C_4-alkoxy, C_1-C_4-alkoxy-C_1-C_4-alkyl-oxy, Het^b and NR^9R^{10};


R^9 is selected from hydrogen and C_1-C_4-alkyl;

R^{10} is selected from hydrogen, C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl, C_1-C_4-alkoxy-C_1-C_4-alkyl and di-C_1-C_4-alkyl-amino-C_1-C_4-alkyl;

wherein Het^b is a 4- or 5- or 6- membered heterocyclic ring comprising 1 or 2 heteroatoms or groups independently selected from N, O, S, SO and SO_2, wherein said heterocyclic ring Het^b is unsubstituted or substituted on a carbon atom with one or two substituents independently selected from C_1-C_4-alkyl, hydroxy, cyano, fluoro, hydroxy-C_1-C_4-alkyl, C_1-C_4-alkoxy and fluoro-C_1-C_4-alkyl, and wherein said heterocyclic ring Het^b is further optionally substituted on a carbon atom by oxo, and wherein the nitrogen atom when present in Het^b is further optionally substituted with C_1-C_4-alkyl which is optionally substituted with 1 to 3 substituents independently selected from fluoro, hydroxy and C_1-C_4-alkoxy;

or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

12. A compound of formula (I) or of formula (Ia), according to any one of the preceding claims, wherein A is selected from the group consisting of:



or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

13. A compound of formula (I) or of formula (Ia) according to claim 12, wherein

R^N is hydrogen or C_1-C_4-alkyl;


R^O is hydrogen or NR^9R^{10};

R^v is independently selected from fluoro, chloro and C_1-C_4-alkyl;

z is 0 or 1;

or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

14. A compound of formula (Ib*),



(Ib*),

wherein A, C, R^{B2}, R^{B3} and R^{B4} are as defined in any one of the preceding claims, wherein A is unsubstituted or substituted as defined in any one of the preceding claims, or a pharmaceutically acceptable salt thereof.

15. A compound according to any one of the preceding claims which is selected from:

1-{6-[(4*M*)-4-(5-Chloro-6-methyl-1*H*-indazol-4-yl)-5-methyl-3-(1-methyl-1*H*-indazol-5-yl)-1*H*-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one,

1-{6-[(4*M*)-4-(5-Chloro-6-methyl-1*H*-indazol-4-yl)-3-(1-{2-[(3*S*)-3-fluoropyrrolidin-1-yl]ethyl}-1*H*-indazol-5-yl)-5-methyl-1*H*-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one,

1-{6-[(4*M*)-4-(5-Chloro-6-methyl-1*H*-indazol-4-yl)-5-methyl-3-phenyl-1*H*-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one,

1-(6-{(4*M*)-4-(5-Chloro-6-methyl-1*H*-indazol-4-yl)-3-[2-(2-methoxyethyl)-2*H*-indazol-5-yl]-5-methyl-1*H*-pyrazol-1-yl}-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one,

1-(6-{(4*M*)-4-(5-Chloro-6-methyl-1*H*-indazol-4-yl)-3-[2-(2-hydroxy-2-methylpropyl)-2*H*-indazol-5-yl]-5-methyl-1*H*-pyrazol-1-yl}-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one,

1-{6-[(4*M*)-4-(5-Chloro-6-methyl-1*H*-indazol-4-yl)-3-{2-[2-(2-methoxyethoxy)ethyl]-2*H*-indazol-5-yl}-5-methyl-1*H*-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one,

1-(6-{(4*M*)-4-(5-Chloro-6-methyl-1*H*-indazol-4-yl)-3-[4-(hydroxymethyl)phenyl]-5-methyl-1*H*-pyrazol-1-yl}-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one,


1-(6-{(4*M*)-4-(5-Chloro-6-methyl-1*H*-indazol-4-yl)-3-[2-fluoro-4-(2-methoxyethoxy)phenyl]-5-methyl-1*H*-pyrazol-1-yl}-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one,

1-(6-{(4*M*)-4-(3-Amino-5-chloro-6-methyl-1*H*-indazol-4-yl)-3-[2-(2-methoxyethyl)-2*H*-indazol-5-yl]-5-methyl-1*H*-pyrazol-1-yl}-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one,

1-{6-[(4*M*)-4-(3-Amino-5-chloro-6-methyl-1*H*-indazol-4-yl)-5-methyl-3-phenyl-1*H*-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one,

or a pharmaceutically acceptable salt thereof.

16. A compound with the following structure:



, or a pharmaceutically acceptable salt thereof.

17. A compound according to any one of the preceding claims, or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a crystalline form

thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof, for use as a medicament.

18. Use of a compound according to any one of the preceding claims, or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a crystalline form thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof in the manufacture of a medicament for the treatment of a cancer or a solid tumor.

19. A pharmaceutical composition comprising a compound according to any one of the preceding claims, or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a crystalline form thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof, and at least one pharmaceutically acceptable excipient.